Incyte and MedImmune collaborate on cancer immunotherapies

AstraZeneca (AZN -0.3%) biologics R&D unit MedImmune and Incyte (INSY -6%) collaborate on a Phase 1/2 clinical trial to evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor MEDI4736 in combination with Incyte's oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360.

MEDI4736 blocks the signals that help tumors avoid detection by the immune system while INCB24360 enhances immune cells' ability to fight the tumor.

The two firms collaborate on a non-exclusive basis. They expect the Phase 1 trial to establish a recommended dose regimen and Phase 2 to assess the safety and efficacy of the combination. Further development of the combo is contingent on the results of the trials.

From other sites
Comments (1)
  • 413105
    , contributor
    Comments (3) | Send Message
    The combination immunotherapy of Anti-PD-L1 & IDO inhibitor should show a synergistic efficacy in combating cancer. As, a stage IV cancer survivor, I been researching combination for almost 10 years. The cure for cancer will be from combinatorial immunotherapy.



    Best regards,


    jimmy B
    14 May 2014, 10:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs